So Hee Kim

Dr. So Hee Kim

College of Pharmacy and Research Institute of Pharmaceutical Science and Technology, Ajou University, Suwon 16499, Korea
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SLSoo Jeong Lim
Soo Jeong Lim
SHSoon-Seok Hong
Soon-Seok Hong
JCJu Yeon Choi
Ju Yeon Choi
JKJong Oh Kim
Jong Oh Kim
MLMi-Kyung Lee
Mi-Kyung Lee
SKSo Hee Kim
So Hee Kim
Studies have highlighted the challenge of developing injectable liposomes as a paclitaxel (PTX) carrier, a challenge attributable to the limitations in liposomal stability caused by PTX loading. Poor stability of PTX-loaded liposomes is caused by PTX-triggered aggregation or fusion of liposomal membranes and is exacerbated in the presence of PEGylated lipid. In the present study, the effect of triglyceride incorporation on the stability of PTX-loaded/PEGylated liposomes was explored. Incorporation of a medium chain triglyceride Captex 300 into saturated phosphatidylcholine (PC)-based liposomes (1,2-dimyristoyl-sn-glycero-3-phosphocholine [DMPC]:cholesterol [CHOL]:N-(Carbonyl-methoxypolyethyleneglycol 2000)-1, 2-distearoyl-sn-glycero-3-phospho-ethanolamine [PE-PEG]), produced a fine, homogeneous, and membrane-filterable PTX-loaded liposomes fulfilling the requirement of an injectable lipid formulation. Triglyceride incorporation also greatly inhibited the time-dependent leakage of PTX from saturated PC-based liposomes, which appears to be mediated by the inhibition of liposome fusion. In contrast, triglyceride incorporation induced the destabilization and PTX leakage of unsaturated PC-based liposomes, indicating the opposite effect of triglyceride depending on the fluidity status of PC constituting the liposomal membrane. PTX release profile and the in vitro and in vivo anticancer efficacy of triglyceride-incorporated DMPC:CHOL:PE-PEG liposomes were similar to Taxol® while the toxicity of liposomal PTX was significantly lower than that of Taxol. Taken together, triglyceride incorporation provided an injectable PTX formulation by functioning as a formulation stabilizer of PEGylated/saturated PC-based liposomes.

10 August 2018 in Biomolecules & Therapeutics
Verified
Journal Article
Open access
SBSung Hun Bae
Sung Hun Bae
JPJu Ho Park
Ju Ho Park
HCHyeon Gyeom Choi
Hyeon Gyeom Choi
HKHyesook Kim
Hyesook Kim
SKSo Hee Kim
So Hee Kim
Breast cancer is currently the most prevalent cancer in women, and its incidence increases every year. Azole antifungal drugs were recently found to have antitumor efficacy in several cancer types. They contain an imidazole (clotrimazole and ketoconazole) or a triazole (fluconazole and itraconazole) ring. Using human breast adenocarcinoma cells (MCF-7 and MDA-MB-231), we evaluated the effects of azole drugs on cell proliferation, apoptosis, cell cycle, migration, and invasion, and investigated the underlying mechanisms. Clotrimazole and ketoconazole inhibited the proliferation of both cell lines while fluconazole and itraconazole did not. In addition, clotrimazole and ketoconazole inhibited the motility of MDA-MB-231 cells and induced G1-phase arrest in MCF-7 and MDA-MB-231 cells, as determined by cell cycle analysis and immunoblot data. Moreover, Transwell invasion and gelatin zymography assays revealed that clotrimazole and ketoconazole suppressed invasiveness through the inhibition of matrix metalloproteinase 9 in MDA-MB-231 cells, although no significant changes in invasiveness were observed in MCF-7 cells. There were no significant changes in any of the observed parameters with fluconazole or itraconazole treatment in either breast cancer cell line. Taken together, imidazole antifungal drugs showed strong antitumor activity in breast cancer cells through induction of apoptosis and G1 arrest in both MCF-7 and MDA-MB-231 cells and suppression of invasiveness via matrix metalloproteinase 9 inhibition in MDA-MB-231 cells. Imidazole drugs have well-established pharmacokinetic profiles and known toxicity, which can make these generic drugs strong candidates for repositioning as antitumor therapies.

1 April 2015 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SHSoon-Seok Hong
Soon-Seok Hong
SKSo Hee Kim
So Hee Kim
SLSoo Jeong Lim
Soo Jeong Lim

5 July 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JLJi Sang Lee
Ji Sang Lee
SKSo Hee Kim
So Hee Kim
This study investigated the pharmacokinetics of tofacitinib in rats and the effects of first-pass metabolism on tofacitinib pharmacokinetics. Intravenous administration of 5, 10, 20, and 50 mg/kg tofacitinib showed that the dose-normalized area under the plasma concentration-time curve from time zero to infinity (AUC) was significantly higher at 50 mg/kg than at lower doses, a difference possibly due to saturation of the hepatic metabolism of tofacitinib. Oral administration of 10, 20, 50, and 100 mg/kg tofacitinib showed that the dose-normalized AUC was significantly higher at 100 mg/kg than at lower doses, a difference possibly due to saturation of the intestinal metabolism of tofacitinib. Following oral administration of 10 mg/kg tofacitinib, the unabsorbed fraction from the rat intestine was 3.16% and the bioavailability (F) was 29.1%. The AUC was significantly lower (49.3%) after intraduodenal, compared to intraportal, administration, but did not differ between intragastric and intraduodenal administration, suggesting that approximately 46.1% of orally administered tofacitinib was metabolized through an intestinal first-pass effect. The AUC was also significantly lower (42%) after intraportal, compared to intravenous, administration, suggesting that the hepatic first-pass effect on tofacitinib after entering the portal vein was approximately 21.3% of the oral dose. Taken together, these findings suggest that the low F of tofacitinib is due primarily to intestinal first-pass metabolism.

1 April 2014 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
NRNithya Ramnath
Nithya Ramnath
Ernest NadalErnest Nadal
Ernest Nadal
CJChae Kyung Jeon
Chae Kyung Jeon
JSJuan Sandoval
Juan Sandoval
JCJustin Colacino
Justin Colacino
SKSo Hee Kim
So Hee Kim
1α,25-Dihydroxyvitamin D3 (1,25-D3, calcitriol) is the most active form of vitamin D and has antineoplastic activity at supraphysiologic doses in several cancers both in vitro and in vivo.1 x 1 Deeb, KK, Trump, DL, and Johnson, CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007; 7: 684–700 Crossref | PubMed | Scopus (858) | Google Scholar See all References At these doses, 1,25-D3 is associated with antiproliferative activity,2 x 2 Hershberger, PA, Modzelewski, RA, Shurin, ZR, Rueger, RM, Trump, DL, and Johnson, CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Res. 1999; 59: 2644–2649 PubMed | Google Scholar See all References , 3 x 3 Koshizuka, K, Koike, M, Asou, H et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat. 1999; 53: 113–120 Crossref | PubMed | Scopus (62) | Google Scholar See all References , 4 x 4 McElwain, MC, Modzelewski, RA, Yu, WD, Russell, DM, and Johnson, CS. Vitamin D: an antiproliferative agent with potential for therapy of squamous cell carcinoma. Am J Otolaryngol. 1997; 18: 293–298 Abstract | Full Text PDF | PubMed | Scopus (27) | Google Scholar See all References induction of cell differentiation,5 x 5 Liu, M, Lee, MH, Cohen, M, Bommakanti, M, and Freedman, LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996; 10: 142–153 Crossref | PubMed | Scopus (776) | Google Scholar See all References cell cycle arrest,6 x 6 Yee, SW, Campbell, MJ, and Simons, C. Inhibition of Vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol. 2006; 98: 228–235 Crossref | PubMed | Scopus (36) | Google Scholar See all References apoptosis,7 x 7 Bernardi, RJ, Trump, DL, Yu, WD, McGuire, TF, Hershberger, PA, and Johnson, CS. Combination of 1alpha,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res. 2001; 7: 4164–4173 PubMed | Google Scholar See all References ,8 x 8 McGuire, TF, Trump, DL, and Johnson, CS. Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J Biol Chem. 2001; 276: 26365–26373 Crossref | PubMed | Scopus (116) | Google Scholar See all References and inhibition of angiogenesis.9 x 9 Nakagawa, K, Sasaki, Y, Kato, S, Kubodera, N, and Okano, T. 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis. 2005; 26: 1044–1054 Crossref | PubMed | Scopus (116) | Google Scholar See all References Antiproliferative activity is mediated through the vitamin D receptor (VDR), which is not only found in classic target organs (intestinal tract, kidney and bone) but also in many other epithelial and mesenchymal cells of tissues, such as lung, prostate, and breast. The evidence for a possible role of the vitamin D pathway in lung cancer comes largely from in vitro or in vivo studies. Higashimoto et al.10 x 10 Higashimoto, Y, Ohata, M, Nishio, K et al. 1alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 1996; 16: 2653–2659 PubMed | Google Scholar See all References reported that 1,25-D3 inhibited the growth of lung cancer cell lines and affects cell cycle regulation in squamous cell carcinoma models.11 x 11 Light, BW, Yu, WD, McElwain, MC, Russell, DM, Trump, DL, and Johnson, CS. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system. Cancer Res. 1997; 57: 3759–3764 PubMed | Google Scholar See all References ,12 x 12 Hershberger, PA, McGuire, TF, Yu, WD et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther. 2002; 1: 821–829 PubMed | Google Scholar See all References 1,25-D3 has been shown to inhibit lung tumor growth and lung metastases in mouse models.13 x 13 Young, MR, Ihm, J, Lozano, Y, Wright, MA, and Prechel, MM. Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother. 1995; 41: 37–45 Crossref | PubMed | Scopus (68) | Google Scholar See all References ,14 x 14 Nakagawa, K, Kawaura, A, Kato, S, Takeda, E, and Okano, T. 1 alpha,25-Dihydroxyvitamin D3 is a preventive factor in the metastasis of lung cancer. Carcinogenesis. 2005; 26: 429–440 Crossref | PubMed | Scopus (105) | Google Scholar See all References The antiproliferative effect of 1,25-D3 is related to G1 cell cycle arrest and is directly and inversely proportional to the VDR15 x 15 Kim, SH, Chen, G, King, AN et al. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer. 2012; 77: 265–271 Abstract | Full Text | Full Text PDF | PubMed | Scopus (37) | Google Scholar See all References and CYP24A1 expression, respectively.16 x 16 Chen, G, Kim, SH, King, AN et al. CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma. Clin Cancer Res. 2011; 17: 817–826 Crossref | PubMed | Scopus (65) | Google Scholar See all References

7 May 2020 in Journal of Pharmaceutical Investigation
Verified
Journal Article
Closed access
PDF file
JKJi Eun Kim
Ji Eun Kim
MPMun Young Park
Mun Young Park
SKSo Hee Kim
So Hee Kim